Velacur: Providing patients with early detection of liver disease

Oct 25, 2022
Sonic Incytes' Velacur logo. A purple to light blue gradient made up of polkadots.

One in five Canadians have nonalcoholic fatty liver disease (NAFLD), which can lead to liver cirrhosis and cancer. While there are no drugs on the market, NAFLD can often be reversed with lifestyle changes, such as diet and exercise. Sadly, given that there are often no initial symptoms, patients tend to go undiagnosed until they arrive in the emergency room presenting with cirrhosis.

Sonic Incytes is helping to diagnose liver disease early, so that patients can take necessary steps to manage this condition.

Based in Vancouver, BC, Sonic Incytes has introduced an innovative tool to the market called Velacur™, which aids in the clinical management of patients with liver disease.

Sonic Incytes’ proprietary technology was invented by University of British Columbia professors Tim Salcudean and Robert Rohling. Velacur™ uses an external activation board similar to MRI elastography to generate steady state shear waves through the liver that are then measured via a typical ultrasound. Based on the relative mechanical properties of the different tissues, liver stiffness and fat can be easily and quickly quantified.

As part of their Pilot Fund project with INOVAIT, Sonic Incytes has been developing AI software to improve the ease of use of Velacur for medical professionals who may not be ultrasound specialists. Sonic Incytes hopes to ultimately achieve adoption in primary care, where liver assessment could, over time, become the next vital sign; similar to the way that blood pressure and heart rate is monitored at a visit to the doctor’s office.

Velacur could be transformational by aiding in the detection of liver disease well before the condition progresses to an advanced stage, giving patients the opportunity to change lifestyle habits before it’s too late.

INOVAIT’s Pilot Fund provides support for commercialization-focused R&D projects involving the integration of AI into image-guided therapy technologies. For more information on how to apply, visit inovait.ca/funding. To learn more about Velacur and Sonic Incytes, visit sonicincytes.com.

Partagez ceci sur les réseaux sociaux

En savoir plus sur nous

INOVAIT reveals Canada’s strategic advantages in image-guided therapy and artificial intelligence in latest report

INOVAIT reveals Canada’s strategic advantages in image-guided therapy and artificial intelligence in latest report

INOVAIT, the pan-Canadian innovation network supporting advancements and commercialization in image-guided therapy (IGT) and artificial intelligence (AI), is excited to share their latest report titled, ‘Unlocking Medtech’s Potential: Canada’s Strategic Advantages in Image-Guided Therapy & AI’. Through synthesized insights from interviews with founders and executives from 30 IGT companies in the INOVAIT Network, this new report uncovers the untapped potential of the image-guided therapy sector in Canada.

INOVAIT et le gouvernement du Canada annoncent les bénéficiaires du Fonds pilote d’INOVAIT dont l’objectif est de favoriser les progrès en thérapie guidée par imagerie et en intelligence artificielle

INOVAIT et le gouvernement du Canada annoncent les bénéficiaires du Fonds pilote d’INOVAIT dont l’objectif est de favoriser les progrès en thérapie guidée par imagerie et en intelligence artificielle

INOVAIT, the pan-Canadian innovation network supporting advancements and commercialization in image-guided therapy (IGT) and artificial intelligence (AI), is excited to announce the latest recipients of its Pilot Fund. This competitive funding program is awarded to compelling medical technology projects that harness the transformative power of AI, machine learning, and big data analytics in IGT to advance medical innovation and streamline care.